![]() |
Name |
Colletotricole A
|
Molecular Formula | C9H13NO3S | |
IUPAC Name* |
2-(4-methyl-1,3-thiazol-5-yl)ethyl 2-hydroxypropanoate
|
|
SMILES |
CC1=C(SC=N1)CCOC(=O)C(C)O
|
|
InChI |
InChI=1S/C9H13NO3S/c1-6-8(14-5-10-6)3-4-13-9(12)7(2)11/h5,7,11H,3-4H2,1-2H3
|
|
InChIKey |
ZGLNVJQLWXTZJO-UHFFFAOYSA-N
|
|
Synonyms |
Colletotricole A; 2-(4-methylthiazol-5-yl)-ethyl 2-hydroxypropanoate
|
|
CAS | NA | |
PubChem CID | 137552831 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 215.27 | ALogp: | 1.2 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 14 | QED Weighted: | 0.77 |
Caco-2 Permeability: | -4.406 | MDCK Permeability: | 0.00003410 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.041 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.826 |
30% Bioavailability (F30%): | 0.032 |
Blood-Brain-Barrier Penetration (BBB): | 0.715 | Plasma Protein Binding (PPB): | 56.70% |
Volume Distribution (VD): | 1.071 | Fu: | 59.63% |
CYP1A2-inhibitor: | 0.035 | CYP1A2-substrate: | 0.942 |
CYP2C19-inhibitor: | 0.034 | CYP2C19-substrate: | 0.819 |
CYP2C9-inhibitor: | 0.004 | CYP2C9-substrate: | 0.166 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.238 |
CYP3A4-inhibitor: | 0.009 | CYP3A4-substrate: | 0.395 |
Clearance (CL): | 4.827 | Half-life (T1/2): | 0.846 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.672 |
Drug-inuced Liver Injury (DILI): | 0.861 | AMES Toxicity: | 0.079 |
Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.126 |
Skin Sensitization: | 0.538 | Carcinogencity: | 0.08 |
Eye Corrosion: | 0.012 | Eye Irritation: | 0.498 |
Respiratory Toxicity: | 0.172 |